Rifat Pamukcu
Director/Board Member bei APREA THERAPEUTICS, INC.
Vermögen: 116 834 $ am 31.03.2024
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Bernard Rudnick | M | - |
Virion Therapeutics LLC
Virion Therapeutics LLC BiotechnologyHealth Technology Virion Therapeutics LLC develops chronic viral disease vaccines. It offers ChiVax and ChiVax-gD vaccines. The firm engages in developing immune-based treatments for virally-associated cancers and chronic viral infections. The company was founded by Bernard C. Rudnick, Hildegund C. J. Ertl and Andrew D. Luber in 2018 and is headquartered in Newark, DE.
Atrin Pharmaceuticals LLC
Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | 9 Jahre |
Andrew Luber | M | - |
Virion Therapeutics LLC
Virion Therapeutics LLC BiotechnologyHealth Technology Virion Therapeutics LLC develops chronic viral disease vaccines. It offers ChiVax and ChiVax-gD vaccines. The firm engages in developing immune-based treatments for virally-associated cancers and chronic viral infections. The company was founded by Bernard C. Rudnick, Hildegund C. J. Ertl and Andrew D. Luber in 2018 and is headquartered in Newark, DE. | 6 Jahre |
Michael Grissinger | M | 70 |
Atrin Pharmaceuticals LLC
Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | 6 Jahre |
John Hamill | M | 60 | 1 Jahre | |
Robert J. Towarnicki | M | - |
SIRPant Immunotherapeutics, Inc.
SIRPant Immunotherapeutics, Inc. BiotechnologyHealth Technology SIRPant Immunotherapeutics, Inc. is a clinical-stage immuno-oncology company based in Hummelstown, PA. The company specializes in developing next-generation macrophage-based immunotherapies for the treatment of hematological malignancies and solid tumors. The cell therapy technology employed by SIRPant is based on the reduction of SIRP? expression combined with activation of the patient's own macrophages. This population of SIRP?low activated macrophages is designed to attack the tumor following injection by activating the patient's immune system to produce broad-spectrum anti-tumor activity that utilizes patient T-cells and antibodies targeting cancer neoantigens. The company was founded by Richard F. Fitzgerald, and the CEO is Robert J. Towarnicki. | - |
Oren Gilad | M | 56 | 2 Jahre | |
Richard Peters | M | 61 | 4 Jahre | |
Kristina Rinker | M | - |
Syantra, Inc.
Syantra, Inc. Miscellaneous Commercial ServicesCommercial Services Syantra, Inc. engages in the development of cancer detection and treatment technology. It offers Syantra DX - Breast Cancer, a blood-based cancer detection assay that utilizes a novel suite of biomarkers and proprietary artificial intelligence-generated algorithms to provide a positive or negative result. The company was founded by Kristina Rinker and Kenneth Fuh and is headquartered in Calgary, Canada. | - |
Bernd Seizinger | M | 67 | 9 Jahre | |
Marc Duey | M | 68 | 2 Jahre | |
John Henneman | M | 62 | 5 Jahre | |
Gabriela Gruia | M | 67 | 1 Jahre | |
Kenneth Fuh | M | - |
Syantra, Inc.
Syantra, Inc. Miscellaneous Commercial ServicesCommercial Services Syantra, Inc. engages in the development of cancer detection and treatment technology. It offers Syantra DX - Breast Cancer, a blood-based cancer detection assay that utilizes a novel suite of biomarkers and proprietary artificial intelligence-generated algorithms to provide a positive or negative result. The company was founded by Kristina Rinker and Kenneth Fuh and is headquartered in Calgary, Canada. | - |
Robert Shepherd | M | - |
Syantra, Inc.
Syantra, Inc. Miscellaneous Commercial ServicesCommercial Services Syantra, Inc. engages in the development of cancer detection and treatment technology. It offers Syantra DX - Breast Cancer, a blood-based cancer detection assay that utilizes a novel suite of biomarkers and proprietary artificial intelligence-generated algorithms to provide a positive or negative result. The company was founded by Kristina Rinker and Kenneth Fuh and is headquartered in Calgary, Canada. | - |
Renold Capocasale | M | - |
Atrin Pharmaceuticals LLC
Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | - |
Williamson Z. Bradford | M | 62 |
Virion Therapeutics LLC
Virion Therapeutics LLC BiotechnologyHealth Technology Virion Therapeutics LLC develops chronic viral disease vaccines. It offers ChiVax and ChiVax-gD vaccines. The firm engages in developing immune-based treatments for virally-associated cancers and chronic viral infections. The company was founded by Bernard C. Rudnick, Hildegund C. J. Ertl and Andrew D. Luber in 2018 and is headquartered in Newark, DE. | 3 Jahre |
Hildegund C. J. Ertl | M | - |
Virion Therapeutics LLC
Virion Therapeutics LLC BiotechnologyHealth Technology Virion Therapeutics LLC develops chronic viral disease vaccines. It offers ChiVax and ChiVax-gD vaccines. The firm engages in developing immune-based treatments for virally-associated cancers and chronic viral infections. The company was founded by Bernard C. Rudnick, Hildegund C. J. Ertl and Andrew D. Luber in 2018 and is headquartered in Newark, DE. | 6 Jahre |
John Fucci | M | - |
SIRPant Immunotherapeutics, Inc.
SIRPant Immunotherapeutics, Inc. BiotechnologyHealth Technology SIRPant Immunotherapeutics, Inc. is a clinical-stage immuno-oncology company based in Hummelstown, PA. The company specializes in developing next-generation macrophage-based immunotherapies for the treatment of hematological malignancies and solid tumors. The cell therapy technology employed by SIRPant is based on the reduction of SIRP? expression combined with activation of the patient's own macrophages. This population of SIRP?low activated macrophages is designed to attack the tumor following injection by activating the patient's immune system to produce broad-spectrum anti-tumor activity that utilizes patient T-cells and antibodies targeting cancer neoantigens. The company was founded by Richard F. Fitzgerald, and the CEO is Robert J. Towarnicki. | 3 Jahre |
Michelle Nanjad | F | - |
Syantra, Inc.
Syantra, Inc. Miscellaneous Commercial ServicesCommercial Services Syantra, Inc. engages in the development of cancer detection and treatment technology. It offers Syantra DX - Breast Cancer, a blood-based cancer detection assay that utilizes a novel suite of biomarkers and proprietary artificial intelligence-generated algorithms to provide a positive or negative result. The company was founded by Kristina Rinker and Kenneth Fuh and is headquartered in Calgary, Canada. | - |
Travis Whitfull | M | - |
SIRPant Immunotherapeutics, Inc.
SIRPant Immunotherapeutics, Inc. BiotechnologyHealth Technology SIRPant Immunotherapeutics, Inc. is a clinical-stage immuno-oncology company based in Hummelstown, PA. The company specializes in developing next-generation macrophage-based immunotherapies for the treatment of hematological malignancies and solid tumors. The cell therapy technology employed by SIRPant is based on the reduction of SIRP? expression combined with activation of the patient's own macrophages. This population of SIRP?low activated macrophages is designed to attack the tumor following injection by activating the patient's immune system to produce broad-spectrum anti-tumor activity that utilizes patient T-cells and antibodies targeting cancer neoantigens. The company was founded by Richard F. Fitzgerald, and the CEO is Robert J. Towarnicki. | - |
Kevin D. Smith | M | - |
Atrin Pharmaceuticals LLC
Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | - |
Katherine High | M | 72 |
Virion Therapeutics LLC
Virion Therapeutics LLC BiotechnologyHealth Technology Virion Therapeutics LLC develops chronic viral disease vaccines. It offers ChiVax and ChiVax-gD vaccines. The firm engages in developing immune-based treatments for virally-associated cancers and chronic viral infections. The company was founded by Bernard C. Rudnick, Hildegund C. J. Ertl and Andrew D. Luber in 2018 and is headquartered in Newark, DE. | - |
Robert Lozuk | M | - |
Syantra, Inc.
Syantra, Inc. Miscellaneous Commercial ServicesCommercial Services Syantra, Inc. engages in the development of cancer detection and treatment technology. It offers Syantra DX - Breast Cancer, a blood-based cancer detection assay that utilizes a novel suite of biomarkers and proprietary artificial intelligence-generated algorithms to provide a positive or negative result. The company was founded by Kristina Rinker and Kenneth Fuh and is headquartered in Calgary, Canada. | 1 Jahre |
Benjamin R. Cowen | M | 63 |
Atrin Pharmaceuticals LLC
Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | 12 Jahre |
M. Berrey | M | 57 |
Virion Therapeutics LLC
Virion Therapeutics LLC BiotechnologyHealth Technology Virion Therapeutics LLC develops chronic viral disease vaccines. It offers ChiVax and ChiVax-gD vaccines. The firm engages in developing immune-based treatments for virally-associated cancers and chronic viral infections. The company was founded by Bernard C. Rudnick, Hildegund C. J. Ertl and Andrew D. Luber in 2018 and is headquartered in Newark, DE. | 3 Jahre |
Jean Bizzari | M | 69 | 1 Jahre | |
Jeffrey Dayno | M | 66 |
Atrin Pharmaceuticals LLC
Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | 8 Jahre |
Zeev Weiss | M | 62 | 2 Jahre | |
Elaine Petrof | M | - |
Midway Pharmaceuticals, Inc.
Midway Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Midway Pharmaceuticals, Inc. develops non-antibiotic therapies. It capitalizes on the finding the molecular weight polymers, taken orally but not systemically absorbed, can inhibit the pathogenic behavior of bacteria in the GI tract, enhance gut barrier function and promote gastrointestinal healing. The company was founded by John Alverdy, Eugene Chang and Elaine Petrof in 2005 and is headquartered in Spring House, PA. | 19 Jahre |
John Alverdy | M | - |
Midway Pharmaceuticals, Inc.
Midway Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Midway Pharmaceuticals, Inc. develops non-antibiotic therapies. It capitalizes on the finding the molecular weight polymers, taken orally but not systemically absorbed, can inhibit the pathogenic behavior of bacteria in the GI tract, enhance gut barrier function and promote gastrointestinal healing. The company was founded by John Alverdy, Eugene Chang and Elaine Petrof in 2005 and is headquartered in Spring House, PA. | 19 Jahre |
Alice Reimer | F | 51 |
Syantra, Inc.
Syantra, Inc. Miscellaneous Commercial ServicesCommercial Services Syantra, Inc. engages in the development of cancer detection and treatment technology. It offers Syantra DX - Breast Cancer, a blood-based cancer detection assay that utilizes a novel suite of biomarkers and proprietary artificial intelligence-generated algorithms to provide a positive or negative result. The company was founded by Kristina Rinker and Kenneth Fuh and is headquartered in Calgary, Canada. | - |
Harry F. Arader | M | - |
Midway Pharmaceuticals, Inc.
Midway Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Midway Pharmaceuticals, Inc. develops non-antibiotic therapies. It capitalizes on the finding the molecular weight polymers, taken orally but not systemically absorbed, can inhibit the pathogenic behavior of bacteria in the GI tract, enhance gut barrier function and promote gastrointestinal healing. The company was founded by John Alverdy, Eugene Chang and Elaine Petrof in 2005 and is headquartered in Spring House, PA. | - |
Mitchell Fink | M | - |
Midway Pharmaceuticals, Inc.
Midway Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Midway Pharmaceuticals, Inc. develops non-antibiotic therapies. It capitalizes on the finding the molecular weight polymers, taken orally but not systemically absorbed, can inhibit the pathogenic behavior of bacteria in the GI tract, enhance gut barrier function and promote gastrointestinal healing. The company was founded by John Alverdy, Eugene Chang and Elaine Petrof in 2005 and is headquartered in Spring House, PA. | - |
Eugene Chang | M | - |
Midway Pharmaceuticals, Inc.
Midway Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Midway Pharmaceuticals, Inc. develops non-antibiotic therapies. It capitalizes on the finding the molecular weight polymers, taken orally but not systemically absorbed, can inhibit the pathogenic behavior of bacteria in the GI tract, enhance gut barrier function and promote gastrointestinal healing. The company was founded by John Alverdy, Eugene Chang and Elaine Petrof in 2005 and is headquartered in Spring House, PA. | 19 Jahre |
Jay R. Rosan | M | 79 |
Atrin Pharmaceuticals LLC
Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | - |
Thomas Penn | M | 78 |
Virion Therapeutics LLC
Virion Therapeutics LLC BiotechnologyHealth Technology Virion Therapeutics LLC develops chronic viral disease vaccines. It offers ChiVax and ChiVax-gD vaccines. The firm engages in developing immune-based treatments for virally-associated cancers and chronic viral infections. The company was founded by Bernard C. Rudnick, Hildegund C. J. Ertl and Andrew D. Luber in 2018 and is headquartered in Newark, DE. | - |
Sue Currie | M | - |
Virion Therapeutics LLC
Virion Therapeutics LLC BiotechnologyHealth Technology Virion Therapeutics LLC develops chronic viral disease vaccines. It offers ChiVax and ChiVax-gD vaccines. The firm engages in developing immune-based treatments for virally-associated cancers and chronic viral infections. The company was founded by Bernard C. Rudnick, Hildegund C. J. Ertl and Andrew D. Luber in 2018 and is headquartered in Newark, DE. | 3 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Christian Schade | M | 63 | 7 Jahre | |
Michael Kelly | M | 67 | 2 Jahre | |
Richard Fitzgerald | M | 60 |
SIRPant Immunotherapeutics, Inc.
SIRPant Immunotherapeutics, Inc. BiotechnologyHealth Technology SIRPant Immunotherapeutics, Inc. is a clinical-stage immuno-oncology company based in Hummelstown, PA. The company specializes in developing next-generation macrophage-based immunotherapies for the treatment of hematological malignancies and solid tumors. The cell therapy technology employed by SIRPant is based on the reduction of SIRP? expression combined with activation of the patient's own macrophages. This population of SIRP?low activated macrophages is designed to attack the tumor following injection by activating the patient's immune system to produce broad-spectrum anti-tumor activity that utilizes patient T-cells and antibodies targeting cancer neoantigens. The company was founded by Richard F. Fitzgerald, and the CEO is Robert J. Towarnicki. | 1 Jahre |
Scott Coiante | M | 57 | 4 Jahre | |
Fouad Namouni | M | 55 | 2 Jahre | |
Gregory Korbel | M | 48 | 7 Jahre | |
Lars Abrahmsén | M | 66 | 8 Jahre | |
Travis Whitfill | M | 34 |
SIRPant Immunotherapeutics, Inc.
SIRPant Immunotherapeutics, Inc. BiotechnologyHealth Technology SIRPant Immunotherapeutics, Inc. is a clinical-stage immuno-oncology company based in Hummelstown, PA. The company specializes in developing next-generation macrophage-based immunotherapies for the treatment of hematological malignancies and solid tumors. The cell therapy technology employed by SIRPant is based on the reduction of SIRP? expression combined with activation of the patient's own macrophages. This population of SIRP?low activated macrophages is designed to attack the tumor following injection by activating the patient's immune system to produce broad-spectrum anti-tumor activity that utilizes patient T-cells and antibodies targeting cancer neoantigens. The company was founded by Richard F. Fitzgerald, and the CEO is Robert J. Towarnicki. | 2 Jahre |
Teresa Wright | M | - |
Virion Therapeutics LLC
Virion Therapeutics LLC BiotechnologyHealth Technology Virion Therapeutics LLC develops chronic viral disease vaccines. It offers ChiVax and ChiVax-gD vaccines. The firm engages in developing immune-based treatments for virally-associated cancers and chronic viral infections. The company was founded by Bernard C. Rudnick, Hildegund C. J. Ertl and Andrew D. Luber in 2018 and is headquartered in Newark, DE. | - |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 40 | 86,96% |
Kanada | 6 | 13,04% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Rifat Pamukcu
- Persönliches Netzwerk